However, Immunotherapy by PD1 blockade combined with VEGF blockade plus chemotherapy significantly improved progression-free survival (PFS) and overall survival (OS) among patients with metastatic nonsquamous NSCLC with EGFR or ALK genetic alteration status (medium 9.7 months versus 6.1 months), suggesting that immunotherapy is a major area of research for therapy in EGFR-TKI resistant patients [24], especially in East Asian NSCLC patients. This evidence concerns the gene ALK and non-small cell lung carcinoma.